OSSA: Ophthalmological Society of South Africa’s Post

Retina biosimilar news from Market Scope: Amgen has launched its Eylea biosimilar, #Pavblu (aflibercept-ayyh), after a victory in October in its patent fight with Regeneron. Pavblu was approved in August 2024 for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. #retina #biosimilars #patent #legal #productlaunch

Check out AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma. Phase 1a study explored the safety, tolerability, and pharmacokinetics of our compound, which is promising new medication for chronic stable angina. Now that the meeting’s embargo has lifted, we’re thrilled to share these results with you! Check out the attached presentation for more details. If you’d like the full version of the deck, feel free to reach out directly to Uwe Tigör, MD or Jedrzej Litwiniuk, MHA. #cardiology #CSAP #AUX001 #ESC #newmedication #biotech #news

You didn't think we were finished with our Hawaiian Eye & Retina coverage, did you? 🏝 Jay Pepose, MD, PhD, discusses a multicenter trial that compared different techniques of determining ocular dominance, and how it pertains to #monovision. “We have to rethink the whole paradigm of ocular dominance,” he said. 🔗👇 #OcularSurgeryNews #Ophthalmology #HawaiianEyeMeeting #Cataractsurgery #Ophthalmologist https://lnkd.in/emdvHMmA

𝙎𝙘𝙞𝙖𝙩𝙞𝙘𝙖 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙈𝙖𝙧𝙠𝙚𝙩 𝙍𝙚𝙨𝙩𝙧𝙖𝙞𝙣𝙩𝙨 𝙖𝙣𝙙 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 #Sciatica is a #condition that is caused by #irritation or #compression of the #sciatic #nerve, which #runs from the #lower #back, #down the #back of #each #leg. It is a common cause of #lower #back and #leg #pain that can #range from #mild to #severe. Sciatica can be caused by a variety of #conditions, such as a #slipped #disc, #spinal #stenosis, #degenerative #disc #disease, or a #pinched #nerve. Treatment for sciatica is typically non-surgical and is aimed at #reducing #pain and #restoring #normal #function. Treatment options often depend on the #underlying cause of the sciatica. #Non-#surgical #treatments may include #physical #therapy, #medications, #lifestyle #modifications, and #injections. ✅ 𝗚𝗿𝗮𝗯 𝗣𝗗𝗙 𝗙𝗼𝗿 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: https://lnkd.in/eazkQHcR 𝙍𝙚𝙨𝙩𝙧𝙖𝙞𝙣𝙩𝙨 & 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 Sciatica treatment is a complex process that requires an understanding of the underlying causes of the condition. There are a variety of treatments available, and the effectiveness of each is dependent on the underlying cause of the sciatica. As such, one of the key restraints and challenges in sciatica treatment is determining the cause of the condition. This can be difficult to identify, as there are many potential causes, including herniated discs, spinal stenosis, spondylolisthesis, piriformis syndrome, and others. Additionally, some of these conditions may require imaging, such as an MRI or CT scan, to properly diagnose. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨 The Sciatica Treatment market includes players such as Abbott Laboratories(US), Johnson & Johnson(US), Teva Pharmaceutical Industries Ltd.(IS), Sun Pharmaceutical Industries Ltd.(IN), . Sorrento Therapeutics, Inc.(US), Alkem Laboratories Ltd.(IN), Amneal Pharmaceuticals, Inc.(US),. Aurobindo Pharma Limited(IN), . Novartis AG(CH), Cadila Healthcare Ltd.(IN).

As the role of lipids in neurodegenerative diseases such as Parkinson’s Disease is increasingly acknowledged, it has become essential to consider what lipids may have a hand in neuropathology. MSI SPLASH is made specifically for Mass Spec Imaging of neurological tissue. The mixture of thirteen internal standards is designed to be applied to brain sections using a sprayer, similarly to the application of matrix for MALDI. MSI SPLASH allows not only for quantitation of lipids within the brain, but also localization of those lipids to provide more detailed information for answering biological questions. https://ow.ly/Eb4E50Rcvc6

Check out AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma.   Phase 1a study explored the safety, tolerability, and pharmacokinetics of our compound, which is promising new medication for chronic stable angina.   Now that the meeting’s embargo has lifted, we’re thrilled to share these results with you! Check out the attached presentation for more details.   If you’d like the full version of the deck, feel free to reach out directly to Uwe Tigör, MD or Jedrzej Litwiniuk, MHA.   #cardiology #CSAP #AUX001 #ESC #newmedication #biotech #news

Check out AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma. Phase 1a study explored the safety, tolerability, and pharmacokinetics of our compound, which is promising new medication for chronic stable angina. Now that the meeting’s embargo has lifted, we’re thrilled to share these results with you! Check out the attached presentation for more details. If you’d like the full version of the deck, feel free to reach out directly to @Uwe Tigör, MD or to me #cardiology #CSAP #AUX001 #ESC #newmedication #biotech #news

Thank you Simon King and FirstWord Group for interviewing our CEO Frederic Guerard about innovations in the field of wet AMD and the important work Opthea is doing to deliver superior vision to patients with wet AMD by developing sozinibercept, its novel, first-in-class anti-VEGF-C/D ‘trap’ inhibitor in combination with current standard-of-care anti-VEGF-A therapies. Learn about our pivotal Phase 3 trials that will read out in 2025 (COAST in early Q2 2025, ShORe in mid 2025) and how sozinibercept fits into the current wet AMD treatment landscape. Read the full interview: https://lnkd.in/eRF25eGF   #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #biopharma #eyehealth #retinaspecialists #innovation #sozinibercept

We started a longitudinal study to assess imaging biomarkers in relation to new bone formation and inflammatory characteristics in patients with axial spondyloarthritis and psoriatic arthritis together with COPECARE and the department of radiology of Herlev og Gentofte Hospital. Earlier studies (Refs: Willesen ST, et al. Ann Rheum Dis 2024; Jans LBO, et al. Radiology 2022) demonstrated the ability of #BoneMRI to detect structural changes in these populations, however this study investigates the effect of treatment with a pharmaceutical compound and the ability to detect structural bone changes in an early phase. Paper: https://lnkd.in/e9FkQxJs Willesen ST, et al. Ann Rheum Dis 2024. Simone Tromborg Willesen Mikkel Østergaard Rigshospitalet #BoneMRI #Spondyloarthritis #EarlyDetection #MRI